ABP-671 for Gout Patients on Allopurinol
Drug-Drug Interaction Study of ABP-671 in Gout Patients
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 20 (estimated)
- Sponsor
- Atom Therapeutics Co., Ltd · Industry
This trial is looking for adults with gout who are already taking Allopurinol. Participants will take ABP-671 while continuing their Allopurinol therapy to see how the two medicines interact.
You may be able to join if
- I am 18 to 75 years old.
- I have been diagnosed with gout.
- I have been taking Allopurinol daily for at least 14 days.
- I have normal kidney function or moderate kidney impairment.
You may not be able to join if
- I have significant liver problems.
- I have had a serious allergic reaction to Allopurinol.
- I am pregnant or breastfeeding.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThis is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Loading trial locations…